Submit your email address to sign up for the Visionary,
or monthly newletter.

X

Search the Radiation Oncology Institute

X

Submit your email address to sign up for the Visionary,
or monthly newletter.

X

Search the Radiation Oncology Institute

X
Close Index

The Visionary (Spring 2021, Vol. 11, No. 1)

Nominations for 2021 ROI Publication Award Now Open
Help ROI recognize an exceptional early career researcher who has published a practice-changing manuscript in the past year.
Fumiko Chino, MD
Fumiko Chino, MD, is an Assistant Attending at Memorial Sloan Kettering Cancer Center. Learn more about her passion for patient-centered research and why she joined the ROI President’s Circle.
Make Your Annual Gift to the ROI Endure Forever
When you leave a gift for the ROI in your will or other estate plans, it will be invested to provide a steady source of funding for making grants to researchers each year.
Investing in the Future of Radiation Oncology
Hear from new ROI Treasurer James P. Hoey, who is committed to building on the ROI’s research successes while ensuring the long-term sustainability of the organization.
Look for Latest Results of ROI Research in the Red Journal
Two new manuscripts address geographic disparities in the treatment of prostate cancer and the cost effectiveness of SABR for oligometastatic cancer.
 
Issue Index

Look for Latest Results of ROI Research in the Red Journal

Figure 1

This article was published in International Journal of Radiation Oncology •Biology•Physics., Vol. 109, Issue 5, Authors Chad Tang et al, Influence of Geography on Prostate Cancer Treatment, Pg 1286-1295, © Elsevier (2021).

Two ROI research teams have recently published results from their studies in the International Journal of Radiation Oncology • Biology • Physics. Chad Tang, MD, of MD Anderson Cancer Center, led an analysis of the influence of geography on treatment choices for men with prostate cancer. Using data from the National Medicare Database and the AMA Physician Master File, they constructed the first ever set of maps visualizing physician practice patterns across the United States for five prostate cancer treatment options referenced to the number of prostate cancer patients receiving those treatments. Dr. Tang’s team also analyzed how distance between patient and provider influenced the treatment they received.

The study included data from patients diagnosed with prostate cancer between 2011 and 2014 who received definitive treatment with prostatectomy, intensity-modulated radiation therapy (IMRT), brachytherapy, stereotactic body radiation therapy (SBRT) or proton therapy and the active physicians who treated at least one case per year with a particular modality during this period. With this analysis, Dr. Tang and his team were able to demonstrate lower provider availability in rural areas and that greater distance from a treatment type was associated with a decreased likelihood of a patient receiving it. Such evidence is important to documenting disparities and identifying areas of need to improve access to quality cancer care.

The construction of these maps and the analysis of patient-provider distance was a component of the research supported by the Innovative Projects in Radiation Oncology Award that Dr. Tang received from the ROI in 2018 to study barriers to access and costs associated with the most common treatment options for prostate cancer. Dr. Tang’s project, like all the ROI research awards in 2018, sought to answer the question, “How do we improve our ability to get radiation to the patients who need it?” Because prostate cancer is the most common cancer among U.S. men, but many patients are not presented with the full array of radiation treatment options, Dr. Tang and his team wanted to better understand the complex factors underlying these disparities on a national level. The team’s complete methodology and results, including the series of practice pattern maps, were published online in the Red Journal in December 2020 in the article “Influence of Geography on Prostate Cancer Treatment.”

The other article published online in the Red Journal in December and supported in part by ROI funding was “Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of SABR-Comet.” David A. Palma, MD, PhD, received the 2019 ROI Publication Award for his work as the lead author of the manuscript “Stereotactic Ablative Radiotherapy Versus Standard of Care Palliative Treatment in Patients with Oligometastatic Cancers (SABR-COMET): A Randomised Phase 2, Open-Label Trial.” The $5,000 grant that accompanies the ROI Publication Award helped support the cost-effectiveness analysis of the SABR-COMET trial.

These two new articles are evidence of how ROI donors are helping to advance important patient-centered research on high profile topics, such as access to radiotherapy and the use of SABR in the treatment of oligometastatic cancer. See the potentially practice-changing results in the International Journal of Radiation Oncology • Biology • Physics now.